Tumour angiogenesis and angiogenic inhibitors: A review

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 6, 2015, Pages XE01-XE05

  Yadav, Lalita ^a   Puri, Naveen ^a   Rastogi, Varun ^a   Satpute, Pranali ^b   Sharma, Vandana ^a  

^a Kalka Dental College   (India)

^b Department of Prosthodontics   (India)

Author keywords

Angiogenic switch; Angiostatin; Interleukin; VEGF

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; BEVACIZUMAB; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; LONAFARNIB; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN; WORTMANNIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG APPROVAL; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; MACROPHAGE ACTIVATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84935013266     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/12016.6135     Document Type: Review

References (52)

1. Hasina R, Lingen MW. Angiogenesis and oral cancer. Journal of Dental Education. (2001);65(11):1282-90.
2. Gupta MK, Qin RY. Mechanism and its regulation of tumour induced angiogenesis. World journal of gastroenterol. 2003;9(6):1144-55.
3. Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic basis of disease. 7th ed; Philadelphia; Saunders; Elsevier Inc; 2004.
4. Hori A, et al. Suppression of solid tumour growth by immune neutralising monoclonal antibody against human fibroblast growth factor. Cancer Res. 1991;51:6180-84.
5. Carla C, Daris F, Cecilia B, Francesca B, Francesca C, Paolo F. Angiogenesis in head and neck cancer: A review of literature. Journal of oncology. 2012;ID 358472.
6. Folkman J. Tumour Angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia: WB Saunders, 1995:206-32.
7. Bussolino F, Mantovani A, Persico G. Molecular mechanism of blood vessel formation. Trends Biochem Sci. 1997;22:251-56.
8. Ferrara N, Davis Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
9. Kohn S, Nagy JA, Dvorak HF, Dvorak AM. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for hyperpermeability of tumour blood vessels. Lab Invest (1992);67:596-607.
10. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-09.
11. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. (1998);273:13313-16.
12. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J biol. Chem. 1998;273(46):30366-43.
13. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983);219:983-85.
14. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. (1991);5:1806-14.
15. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-58.
16. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol. 2001;280:C1367-74.
17. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9-22.
18. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol3-kinase/Akt signalling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 1997;90:3322-31.
19. Karamysheva AF. Mechanism of angiogenesis. Biochemistry. 2008;73:935-48.
20. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. (1990); (5):519-24.
21. Kim DJ, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour cell growth in vivo. Nature. 1993;362:841-44.
22. Singh RK, Gutman M, Bucana CD, Sanches R, Liansa N, Fidler IJ. Interferons a down regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA. 1995;92:4562-66.
23. Vukanovic J, Issacs JT. Linomide inhibites angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers. Cancer Res. 1995;55:1499-504.
24. Oehler MK, Bicknell R. The promise of anti-angiogenic cancer therapy. Br j Cancer. 2000;82:749-52.
25. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon a mediated downregulation of angiogenesis related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5:2726-34.
26. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist. 2001;6:34-55.
27. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, et al. The functional role of the ELR motif in CXC chemokines-mediated angiogenesis. J Biol Chem. 1995;270:27348-57.
28. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, et al. Macrophage infiltration correlates with tumour stage and angiogenesis in human malignant melanoma. Int J Cancer. 2000;85:182-88.
29. Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang N, Mahvi DM. Interleukin 12 gene transfer in to skin distant from the tumour site elicites antimetastatic effects equivalent to local gene transfer. Hum Gene Ther. 2010;12:149-60.
30. Duda DG, Sunamura M, Lozonschi L, Kodoma T, Egawa S, Matsumoto G, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin-12. Cancer Res. 2000;60:1111-16.
31. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumour growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res. 1999;19:697-703.
32. Fernandez HA, Kallenbach K, Seghezzi G, Grossy E, Colvin S, Schneider R, et al. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res. 1999;82:156-62.
33. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases 2 inhibits bFGF induced human microvascular endothelial cell proliferation. J Cell Physiol. 1993;157:351-58.
34. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, et al. The antitumoural effect of endostatin and angiostatin is associated with a downregulation of vascular endothelial growth factor expression in tumour cells. FASEB J. 2002;16:1802-04.
35. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, et al. Angiogenesis binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA. 1999;96:2811-16.
36. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer; inhibition of tumour growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA. 1998;95:6367-72.
37. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, et al. Endostatin blocks vascular endothelial growth factor mediated signalling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277:27872-79.
38. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGF R2 inhibits vascular expression of Flk-1 and tumour growth in an orthotopic human breast cancer model. Angiogenesis. 2002;5:35-44.
39. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P. Monoclonal antibodies targeting the VEGF receptor 2 as an antiangiogenic therapeutic strategy. Cancer Metastasis Rev. 1998;17:155-61.
40. Im SA, Gomez Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumour growth in vivo. Cancer Res. 1999;59:895-900.
41. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo.Nature.1993;362:841-44.
42. Holash J, Davis S, Papadopoulos N, et al. VEGF Trap: a VEGF blocker with potent antitumour effects. Proc Natl Acad Sci USA. 2002;99:11393-98.
43. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumours. Expert Opin Investing Drugs. 2009;18:821-34.
44. Wilhelm S M, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalling. Mol Cancer Ther. 2008;7:3129-40.
45. Engelman JA. Targetting PI3 signalling in cancer: opportunities, challenges and limitations. Nat Rev cancer. 2009;9:550-62.
46. Jiang BH, Jiang G, Zheng JZ, et al. Phosphatdylinositol 3-kinase signalling controls levels of hypoxia inducible factor 1.Cell growth Differ.2001;12:363-69.
47. Faivre S, Kroemer G, Raymond E. Current development of MTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671-88.
48. Downward J. Targetting Ras signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22.
49. Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther. 2006;6:313-19.
50. Liu M, Bryant MS, Chen J, et al. Antitumour activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumour xenograft models and wap-ras transgenic mice. Cancer Res.1998;58:4947-56.
51. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent TNP–470 is mediated by p53 and p21WAF1/ CIP1. Proc Nat Acad Sci USA. 2000;97:6427-32.
52. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-11.